• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Janssen to Present the Strength and Promise of its Hematologic Malignancies Portfolio and Pipeline at ASH 2021
RARITAN, N.J., November 4, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that more than 45 company-sponsored abstracts, including 11 oral presentations, plus more than 35 investigator-initiated studies will be featured at the American Society of Hematology (ASH) Annual Meeting and Exposition. ASH is taking place at the Georgia World Congress Center in Atlanta and virtually from December 11-14, 2021.“We are committed to advancing the science and treatment of hematologic malignancies and look forward to presenting the latest research from our robust portfolio and pipeline during ASH...
Source: Johnson and Johnson - November 5, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Do No Harm: Stories of Life, Death and Brain Surgery review
Patients see neurosurgeons as gods, but what is the reality? Henry Marsh has written a memoir of startling candourWe go to doctors for help and healing; we don't expect them to make us worse. Most people know the aphorism taught to medical students, attributed to the ancient Greek Hippocrates but timeless in its quiet sanity: "First, do no harm." But many medical treatments do cause harm: learning how to navigate the risks of drug therapies, as well as the catastrophic consequences of botched or inadvised surgical operations, is a big part of why training doctors takes so long. Even the simplest of therapies carries the ri...
Source: Guardian Unlimited Science - March 19, 2014 Category: Science Authors: Gavin Francis Tags: The Guardian Private healthcare Culture Society Reviews Books Neuroscience UK news Hospitals NHS Source Type: news